Marcos Devanir Silva da Costa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marcos Devanir Silva da Costa has a total of 448 co-authors. Here are the top co-authors by number of shared publications:
Sergio Cavalheiro
Department of Neurology and Neurosurgery, Universidade Federal de São Paulo (UNIFESP) , São Paulo, Brazil
42 shared publications- Feres Chaddad-Neto
Department of Neurology and Neurosurgery, Universidade Federal de Sao Paulo, Sao Paulo, SP, Brazil
33 shared publications Feres Chaddad-Neto
24 shared publications- Sergio Cavalheiro
Department of Neurology and Neurosurgery, Federal University of São Paulo, São Paulo, Brazil
16 shared publications - Patricia Alessandra Dastoli
Department of Neurosurgery, Universidade Federal de São Paulo, São Paulo, Brazil
15 shared publications Patricia Alessandra Dastoli
Department of Neurosurgery, Universidade Federal de São Paulo, São Paulo, Brazil
13 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by Springer Nature in Child's Nervous System
- Vol. 42 (1) , 380
Endoscopic third ventriculostomy for diencephalosynapsis-related hydrocephalus in MPDZ gene syndrome: a case report and review of the literature
Purpose: MPDZ syndrome is a rare autosomal recessive disorder caused by biallelic pathogenic variants in MPDZ (9p23) and typically managed with ventriculoperitoneal shunting (VPS). Recent characterization of MPDZ-related hydrocephalus as an obstructive process—driven by diencephalosynapsis and third ventricle atresia—provides theoretical grounds for endoscopic third ventriculostomy (ETV), yet no primary ETV treatment has previously been reported in a genetically confirmed, liveborn patient. Methods: We report a female infant with prenatally diagnosed obstructive ventriculomegaly, subsequently confirmed as MPDZ syndrome by whole-exome sequencing, who was treated with ETV as the primary surgical intervention, and we review the literature on the neurosurgical management of MPDZ-related hydrocephalus. Results: Fetal MRI demonstrated diencephalosynapsis and third ventricle atresia with secondary occlusion of the aqueduct of Sylvius. A ventriculo-amniotic shunt was placed at 29 weeks of gestation; the infant was born at 36 weeks and 1 day and underwent ETV on the fifth day of life without complications. At 2 years and 5 months of age, she developed intermittent symptoms of intracranial hypertension due to late stoma occlusion at the level of the Liliequist membrane, successfully managed with endoscopic stoma revision. At the most recent follow-up (4 years and 5 months), she remains free of ventriculoperitoneal shunting, with age-appropriate neurodevelopment. A systematic review of the literature identified no prior report of ETV used as primary treatment in a genetically confirmed, liveborn patient with MPDZ syndrome. Conclusions: This case provides proof of concept that ETV is both mechanistically justified and clinically effective in selected patients with MPDZ-related obstructive hydrocephalus, potentially avoiding lifelong shunt dependency. Patient selection should nonetheless remain individualized, based on ventricular anatomy, third ventricular floor thickness, and associated structural anomalies.
- 2 October 2026
- Published by Springer Nature in Child's Nervous System
- Vol. 42 (1) , 380
Open AccessEndoscopic third ventriculostomy for diencephalosynapsis-related hydrocephalus in MPDZ gene syndrome: a case report and review of the literature
Purpose: MPDZ syndrome is a rare autosomal recessive disorder caused by biallelic pathogenic variants in MPDZ (9p23) and typically managed with ventriculoperitoneal shunting (VPS). Recent characterization of MPDZ-related hydrocephalus as an obstructive process—driven by diencephalosynapsis and third ventricle atresia—provides theoretical grounds for endoscopic third ventriculostomy (ETV), yet no primary ETV treatment has previously been reported in a genetically confirmed, liveborn patient. Methods: We report a female infant with prenatally diagnosed obstructive ventriculomegaly, subsequently confirmed as MPDZ syndrome by whole-exome sequencing, who was treated with ETV as the primary surgical intervention, and we review the literature on the neurosurgical management of MPDZ-related hydrocephalus. Results: Fetal MRI demonstrated diencephalosynapsis and third ventricle atresia with secondary occlusion of the aqueduct of Sylvius. A ventriculo-amniotic shunt was placed at 29 weeks of gestation; the infant was born at 36 weeks and 1 day and underwent ETV on the fifth day of life without complications. At 2 years and 5 months of age, she developed intermittent symptoms of intracranial hypertension due to late stoma occlusion at the level of the Liliequist membrane, successfully managed with endoscopic stoma revision. At the most recent follow-up (4 years and 5 months), she remains free of ventriculoperitoneal shunting, with age-appropriate neurodevelopment. A systematic review of the literature identified no prior report of ETV used as primary treatment in a genetically confirmed, liveborn patient with MPDZ syndrome. Conclusions: This case provides proof of concept that ETV is both mechanistically justified and clinically effective in selected patients with MPDZ-related obstructive hydrocephalus, potentially avoiding lifelong shunt dependency. Patient selection should nonetheless remain individualized, based on ventricular anatomy, third ventricular floor thickness, and associated structural anomalies.
- Open Access
- 26 May 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (7)
Prediction of personalized therapeutic response in pediatric clivus chordoma: chemoresistance test
Precision medicine has expanded therapeutic options for rare central nervous system tumors, yet actionable molecular targets remain limited in pediatric cases. Functional ex vivo drug-response assays may complement genomic approaches by identifying tumor-specific sensitivities. Clival chordoma is a rare, locally aggressive tumor generally considered chemotherapy-refractory, particularly in children. We report the prospective use of a functional drug-response platform (Bioverso Test) to guide treatment in a pediatric patient with recurrent metastatic clival chordoma. A four-year-old patient with intracranial and pulmonary disease underwent testing using three-dimensional tumor microspheroids. The assay demonstrated broad resistance, with relative sensitivity to irinotecan (CPT-11). Treatment with an irinotecan-based regimen (50 mg/m²/day, days 1-5) resulted in a marked clinical and radiological response after three cycles, with significant reduction of intracranial and pulmonary lesions and no severe toxicities. The response has been sustained for 14 months. This case illustrates the clinical utility of integrating functional drug-response data into real-time decision-making, supporting a role for functional precision oncology in rare and treatment-refractory pediatric tumors.
- 26 May 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (7)
Open AccessPrediction of personalized therapeutic response in pediatric clivus chordoma: chemoresistance test
Precision medicine has expanded therapeutic options for rare central nervous system tumors, yet actionable molecular targets remain limited in pediatric cases. Functional ex vivo drug-response assays may complement genomic approaches by identifying tumor-specific sensitivities. Clival chordoma is a rare, locally aggressive tumor generally considered chemotherapy-refractory, particularly in children. We report the prospective use of a functional drug-response platform (Bioverso Test) to guide treatment in a pediatric patient with recurrent metastatic clival chordoma. A four-year-old patient with intracranial and pulmonary disease underwent testing using three-dimensional tumor microspheroids. The assay demonstrated broad resistance, with relative sensitivity to irinotecan (CPT-11). Treatment with an irinotecan-based regimen (50 mg/m²/day, days 1-5) resulted in a marked clinical and radiological response after three cycles, with significant reduction of intracranial and pulmonary lesions and no severe toxicities. The response has been sustained for 14 months. This case illustrates the clinical utility of integrating functional drug-response data into real-time decision-making, supporting a role for functional precision oncology in rare and treatment-refractory pediatric tumors.
- Open Access
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (08) , 001-007
Recovery estimates and prognostic factors for oculomotor nerve palsy
Third cranial nerve (III CN) palsy is an extremely disabling condition with several etiologies and clinical onsets. Identifying the underlying causes and individual risk factors is critical to determine prognosis and guide treatment. To analyze factors associated with III CN palsy, estimate recovery rates across different etiologies, and identify independent predictors of recovery, considering patient characteristics and comorbidities. A retrospective study was performed, including demographics and neurological data of a consecutive series of patients affected by III CN palsy from 2010 onwards. All patients underwent neurological examination, routine neuroimaging, and follow-up. Kaplan-Meier curve and the log-rank method were used to estimate recovery rates by etiology. Univariate and multivariate logistic regressions assessed patient-specific factors as independent predictors of recovery. Statistical significance was fixed as p-value < 0.05. Overall, 50 patients were included. The prevailing causative factors were microangiopathy in 36% and miscellaneous in 36% of cases. Hypertension (50%), diabetes mellitus (34%), and cardiovascular diseases (14%) were the predominant comorbidities. Total recovery of the oculomotor function was found in 46% of patients. Kaplan-Meier analysis reported microangiopathy and syndromes as etiological factors significantly related to early recovery time. Age and pupillary involvement emerged as significant independent prognostic factors. The etiology significantly influences the recovery estimates of the oculomotor function. At the same time, patients' age, pupillary involvement, and especially hypertension as a comorbidity were the main predictive factors of good outcomes. More extensive studies are required to confirm these findings and include then in clinical practice.
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (08) , 001-007
Open AccessRecovery estimates and prognostic factors for oculomotor nerve palsy
Third cranial nerve (III CN) palsy is an extremely disabling condition with several etiologies and clinical onsets. Identifying the underlying causes and individual risk factors is critical to determine prognosis and guide treatment. To analyze factors associated with III CN palsy, estimate recovery rates across different etiologies, and identify independent predictors of recovery, considering patient characteristics and comorbidities. A retrospective study was performed, including demographics and neurological data of a consecutive series of patients affected by III CN palsy from 2010 onwards. All patients underwent neurological examination, routine neuroimaging, and follow-up. Kaplan-Meier curve and the log-rank method were used to estimate recovery rates by etiology. Univariate and multivariate logistic regressions assessed patient-specific factors as independent predictors of recovery. Statistical significance was fixed as p-value < 0.05. Overall, 50 patients were included. The prevailing causative factors were microangiopathy in 36% and miscellaneous in 36% of cases. Hypertension (50%), diabetes mellitus (34%), and cardiovascular diseases (14%) were the predominant comorbidities. Total recovery of the oculomotor function was found in 46% of patients. Kaplan-Meier analysis reported microangiopathy and syndromes as etiological factors significantly related to early recovery time. Age and pupillary involvement emerged as significant independent prognostic factors. The etiology significantly influences the recovery estimates of the oculomotor function. At the same time, patients' age, pupillary involvement, and especially hypertension as a comorbidity were the main predictive factors of good outcomes. More extensive studies are required to confirm these findings and include then in clinical practice.
- Open Access
- 12 May 2026
- Vol. 84 (4) , 1-7
Mental health and quality of life in patients with ruptured and unruptured cerebral arteriovenous malformation.
Cerebral arteriovenous malformation (cAVM) is a rare and complex cerebrovascular disease that may cause neurological symptoms, cognitive complaints, and psychological distress even without hemorrhage, potentially impairing long-term quality of life. To assess the impact of cAVM on mental health and quality of life, considering patients' clinical presentation and the type of treatment received. In the present cross-sectional study, adults aged 18 to 65 with ruptured or unruptured cAVM treated with conservative, or multimodal approaches were recruited. Data were collected through an online survey distributed by participating institutions. Mental health, psychological distress, and quality of life were evaluated using the 5-item Mental Health Index (MHI-5), the Self-Reporting Questionnaire (SRQ-20), and the World Health Organization Quality of Life-brief version questionnaire (WHOQOL-BREF). Results were categorized and compared with normative data. Statistical analyses included descriptive statistics, analysis of variance (ANOVA), t-tests, χ2, and Fisher's exact tests. Eighty-six participants with cAVM completed the questionnaire. Unruptured lesions accounted for 62.8% and ruptured cAVM 37.2%. Neurological deficits were reported by 94.2% of participants. Among conservatively-managed unruptured cases, 47.1% reported neurological deficits, without significant differences when compared with other treatments. Despite similar neurological status, conservatively managed unruptured patients showed poorer mental health (p = 0.048) and lower quality of life in the physical (p < 0.001) and social domains (p = 0.016). Patients with unruptured cAVM managed conservatively exhibit significantly worse mental health and reduced physical and social quality of life, despite a similar prevalence of neurological deficits relative to other groups. These findings highlight the importance of incorporating psychosocial outcomes into treatment decision-making for cAVM.
- 12 May 2026
- Vol. 84 (4) , 1-7
Open AccessMental health and quality of life in patients with ruptured and unruptured cerebral arteriovenous malformation.
Cerebral arteriovenous malformation (cAVM) is a rare and complex cerebrovascular disease that may cause neurological symptoms, cognitive complaints, and psychological distress even without hemorrhage, potentially impairing long-term quality of life. To assess the impact of cAVM on mental health and quality of life, considering patients' clinical presentation and the type of treatment received. In the present cross-sectional study, adults aged 18 to 65 with ruptured or unruptured cAVM treated with conservative, or multimodal approaches were recruited. Data were collected through an online survey distributed by participating institutions. Mental health, psychological distress, and quality of life were evaluated using the 5-item Mental Health Index (MHI-5), the Self-Reporting Questionnaire (SRQ-20), and the World Health Organization Quality of Life-brief version questionnaire (WHOQOL-BREF). Results were categorized and compared with normative data. Statistical analyses included descriptive statistics, analysis of variance (ANOVA), t-tests, χ2, and Fisher's exact tests. Eighty-six participants with cAVM completed the questionnaire. Unruptured lesions accounted for 62.8% and ruptured cAVM 37.2%. Neurological deficits were reported by 94.2% of participants. Among conservatively-managed unruptured cases, 47.1% reported neurological deficits, without significant differences when compared with other treatments. Despite similar neurological status, conservatively managed unruptured patients showed poorer mental health (p = 0.048) and lower quality of life in the physical (p < 0.001) and social domains (p = 0.016). Patients with unruptured cAVM managed conservatively exhibit significantly worse mental health and reduced physical and social quality of life, despite a similar prevalence of neurological deficits relative to other groups. These findings highlight the importance of incorporating psychosocial outcomes into treatment decision-making for cAVM.
- Open Access
- 8 May 2026
- Published by Springer Nature in Child's Nervous System
- Vol. 42 (1)
PITCH (pediatric infratentorial tumors – hydrocephalus-related complications) registry study design: observational, prospective, multicenter study evaluating the number of surgeries associated with the treatment of hydrocephalus secondary to infratentorial tumors in childhood and adolescence
Introduction: Posterior fossa tumors are the most common solid pediatric neoplasms, and more than 60% of these tumors are associated with hydrocephalus, which can be managed using different strategies, including endoscopic third ventriculostomy (ETV), ventriculoperitoneal shunt (VPS), external ventricular drainage (EVD), or direct tumor resection without CSF diversion. The safest and most effective drainage method remains controversial, and most available studies are limited to single-center retrospective analyses, often constrained by small sample sizes. Therefore, multicenter prospective studies are needed to determine the optimal treatment strategy. Methods: This is a prospective, multicenter cohort study conducted across more than 20 pediatric neurosurgery centers in Latin America. Patients will be allocated into four groups according to the treatment selected for hydrocephalus (ETV, EVD, VPS, or resection). The primary outcome will be the number of surgical interventions related to the treatment of hydrocephalus during the follow-up period. Secondary outcomes will include mortality, infection, and other clinically relevant complications, analyzed as complementary endpoints. Patients will be followed prospectively for up to 12 months after the index procedure, defined as the intervention performed for the treatment of hydrocephalus, and each group will include at least 50 patients. Conclusion: The REDCap online platform will be used for data collection in the PITCH study, enabling prospective data acquisition across multiple centers in Latin America. This will allow comparison of treatment modalities for obstructive hydrocephalus secondary to posterior fossa tumors (ETV, EVD, VPS, and resection) and evaluation of their impact during the first year after diagnosis.
- 8 May 2026
- Published by Springer Nature in Child's Nervous System
- Vol. 42 (1)
Open AccessPITCH (pediatric infratentorial tumors – hydrocephalus-related complications) registry study design: observational, prospective, multicenter study evaluating the number of surgeries associated with the treatment of hydrocephalus secondary to infratentorial tumors in childhood and adolescence
Introduction: Posterior fossa tumors are the most common solid pediatric neoplasms, and more than 60% of these tumors are associated with hydrocephalus, which can be managed using different strategies, including endoscopic third ventriculostomy (ETV), ventriculoperitoneal shunt (VPS), external ventricular drainage (EVD), or direct tumor resection without CSF diversion. The safest and most effective drainage method remains controversial, and most available studies are limited to single-center retrospective analyses, often constrained by small sample sizes. Therefore, multicenter prospective studies are needed to determine the optimal treatment strategy. Methods: This is a prospective, multicenter cohort study conducted across more than 20 pediatric neurosurgery centers in Latin America. Patients will be allocated into four groups according to the treatment selected for hydrocephalus (ETV, EVD, VPS, or resection). The primary outcome will be the number of surgical interventions related to the treatment of hydrocephalus during the follow-up period. Secondary outcomes will include mortality, infection, and other clinically relevant complications, analyzed as complementary endpoints. Patients will be followed prospectively for up to 12 months after the index procedure, defined as the intervention performed for the treatment of hydrocephalus, and each group will include at least 50 patients. Conclusion: The REDCap online platform will be used for data collection in the PITCH study, enabling prospective data acquisition across multiple centers in Latin America. This will allow comparison of treatment modalities for obstructive hydrocephalus secondary to posterior fossa tumors (ETV, EVD, VPS, and resection) and evaluation of their impact during the first year after diagnosis.
- Open Access
- 25 April 2026
- Published by Springer Nature in Child's Nervous System
- Vol. 42 (1)
Galen vein malformation—intrauterine treatment
Introduction: Vein of Galen malformation (VOGM) is a rare and severe congenital arteriovenous malformation. Its therapeutic results are complex and often catastrophic, making its treatment a true challenge. Historical background: VOGM is characterized by the persistence of direct arteriovenous communications between the choroidal feeding arteries and the embryonic vein, known as the median prosencephalic vein of Markowski. Clinical presentation, diagnosis, and pathophysiology: The malformation develops between the 8th and 11th weeks of gestation. Diagnostic suspicion is usually made through fetal ultrasound after the 18th week of gestation or later. Fetal MRI complements the diagnosis. Management, prognosis, and outcomes: There are two groups of patients with VOGM: severe cases, with persistent high-flow arteriovenous shunts leading to multiorgan failure, and mild cases with a lower mortality rate and a more favorable outcome. The use of vascular parameters, based on the diameter of the falcine sinus measured by fetal MRI, can serve as a predictor of neonatal outcome and therapeutic choice. Case report: A 33-year-old primigravida presented with a fetus diagnosed with VOGM by fetal ultrasound at 32 weeks of gestation. An aneurysmal dilation of the Galen vein was observed, with a transverse falcine sinus measuring 10.5 mm. Aneurysm dilatation dimensions: 25 × 21 × 20 mm. Fetal MRI confirmed a falcine sinus width of 10.5 mm, indicating a 96% chance of poor outcome. Fetal embolization of the VOGM was performed, followed by postnatal treatment. Conclusions: In this article, we review the main principles of VOGM management and present a case treated during pregnancy, illustrating a potential therapeutic strategy. We suggest that fetal embolization of VOGM, when appropriately indicated, may represent an emerging approach in the management of this severe condition.
- 25 April 2026
- Published by Springer Nature in Child's Nervous System
- Vol. 42 (1)
Open AccessGalen vein malformation—intrauterine treatment
Introduction: Vein of Galen malformation (VOGM) is a rare and severe congenital arteriovenous malformation. Its therapeutic results are complex and often catastrophic, making its treatment a true challenge. Historical background: VOGM is characterized by the persistence of direct arteriovenous communications between the choroidal feeding arteries and the embryonic vein, known as the median prosencephalic vein of Markowski. Clinical presentation, diagnosis, and pathophysiology: The malformation develops between the 8th and 11th weeks of gestation. Diagnostic suspicion is usually made through fetal ultrasound after the 18th week of gestation or later. Fetal MRI complements the diagnosis. Management, prognosis, and outcomes: There are two groups of patients with VOGM: severe cases, with persistent high-flow arteriovenous shunts leading to multiorgan failure, and mild cases with a lower mortality rate and a more favorable outcome. The use of vascular parameters, based on the diameter of the falcine sinus measured by fetal MRI, can serve as a predictor of neonatal outcome and therapeutic choice. Case report: A 33-year-old primigravida presented with a fetus diagnosed with VOGM by fetal ultrasound at 32 weeks of gestation. An aneurysmal dilation of the Galen vein was observed, with a transverse falcine sinus measuring 10.5 mm. Aneurysm dilatation dimensions: 25 × 21 × 20 mm. Fetal MRI confirmed a falcine sinus width of 10.5 mm, indicating a 96% chance of poor outcome. Fetal embolization of the VOGM was performed, followed by postnatal treatment. Conclusions: In this article, we review the main principles of VOGM management and present a case treated during pregnancy, illustrating a potential therapeutic strategy. We suggest that fetal embolization of VOGM, when appropriately indicated, may represent an emerging approach in the management of this severe condition.
- 12 March 2026
- Published by Springer Nature in Child's Nervous System
- Vol. 42 (1) , 107
Isolated frontosphenoidal suture synostoses: report of two cases and literature review
Introduction Anterior plagiocephaly is most commonly attributed to unilateral coronal synostosis. However, isolated premature fusion of the frontosphenoidal suture (FSC) represents a rare and often misdiagnosed cause due to its overlapping clinical presentation. Accurate diagnosis is essential, as treatment strategies and prognoses differ significantly. Objectives To present a comprehensive literature review of FSC and to report two novel clinical cases—one managed with open fronto-orbital advancement and the other with endoscopic suturectomy. Methods A systematic review of reported FSC cases was performed and supplemented by two patients treated at our institution. Diagnosis was established using cranial computed tomography (CT) with three-dimensional (3D) reconstruction. The first patient underwent open fronto-orbital advancement, while the second was treated with early endoscopic suturectomy. Results In both patients, isolated fusion of the frontosphenoidal suture was confirmed with preservation of the coronal sutures. The first patient, diagnosed at 9 months of age, presented with typical signs of anterior plagiocephaly without the Harlequin sign, and underwent open surgery with excellent postoperative craniofacial symmetry. The second patient, diagnosed earlier due to subtle craniofacial asymmetry, was treated endoscopically with favorable aesthetic results and no postoperative complications. Conclusions FSC represents a rare and underrecognized cause of anterior plagiocephaly. High clinical suspicion is required in cases of atypical cranial asymmetry with open coronal sutures. Cranial CT with 3D reconstruction is essential for accurate diagnosis and identification of the suture involvement. Both open and endoscopic surgical approaches can achieve satisfactory outcomes when appropriately indicated.
- 12 March 2026
- Published by Springer Nature in Child's Nervous System
- Vol. 42 (1) , 107
Isolated frontosphenoidal suture synostoses: report of two cases and literature review
Introduction Anterior plagiocephaly is most commonly attributed to unilateral coronal synostosis. However, isolated premature fusion of the frontosphenoidal suture (FSC) represents a rare and often misdiagnosed cause due to its overlapping clinical presentation. Accurate diagnosis is essential, as treatment strategies and prognoses differ significantly. Objectives To present a comprehensive literature review of FSC and to report two novel clinical cases—one managed with open fronto-orbital advancement and the other with endoscopic suturectomy. Methods A systematic review of reported FSC cases was performed and supplemented by two patients treated at our institution. Diagnosis was established using cranial computed tomography (CT) with three-dimensional (3D) reconstruction. The first patient underwent open fronto-orbital advancement, while the second was treated with early endoscopic suturectomy. Results In both patients, isolated fusion of the frontosphenoidal suture was confirmed with preservation of the coronal sutures. The first patient, diagnosed at 9 months of age, presented with typical signs of anterior plagiocephaly without the Harlequin sign, and underwent open surgery with excellent postoperative craniofacial symmetry. The second patient, diagnosed earlier due to subtle craniofacial asymmetry, was treated endoscopically with favorable aesthetic results and no postoperative complications. Conclusions FSC represents a rare and underrecognized cause of anterior plagiocephaly. High clinical suspicion is required in cases of atypical cranial asymmetry with open coronal sutures. Cranial CT with 3D reconstruction is essential for accurate diagnosis and identification of the suture involvement. Both open and endoscopic surgical approaches can achieve satisfactory outcomes when appropriately indicated.
- Open Access
- 27 February 2026
- Published by Springer Nature in Child's Nervous System
- Vol. 42 (1) , 89
Evaluating temozolomide for pediatric adamantinomatous craniopharyngiomas using microspheroid-based drug screening
Purpose: Pediatric adamantinomatous craniopharyngioma (ACP) is the most common tumor of the diencephalic–pituitary axis in children. Although histologically benign, pediatric ACP is frequently associated with substantial endocrine dysfunction and neurological complications. The gold-standard treatment is complete surgical resection; however, because of the tumor’s location, total removal is often not feasible. Consequently, several authors recommend radiotherapy as an adjuvant option. Nevertheless, partial resections are frequently followed by recurrence, and repeated surgical interventions increase morbidity and impair quality of life. Thus, adjuvant therapeutic strategies capable of controlling this tumor should be encouraged. Methods: We analyzed seven fresh tumor specimens ACP from patients < 18 years of age using a chemoresistance platform ( Bioverso Test , Ziel Biosciences , São Paulo, Brazil). These cases demonstrated widespread resistance to most chemotherapeutic agents tested. Temozolomide (500 µM) was the only drug that showed consistent and significant sensitivity. Results: Based on these findings, we initiated treatment in a 14-year-old patient with recurrent ACP who had previously undergone multiple surgical procedures and radiotherapy. The tumor involved the left cavernous sinus and extended into the sphenoid sinus. Clinically, the patient was amaurotic and presented with panhypopituitarism. The patient received temozolomide (200 mg/m 2 /day for 5 consecutive days in 28-day cycles). After completing 12 cycles of chemotherapy, there was a notable regression of the lesion, with approximately 50% reduction in total tumor volume. Conclusion: These findings suggest that temozolomide may represent a promising therapeutic option for controlling ACP.
- 27 February 2026
- Published by Springer Nature in Child's Nervous System
- Vol. 42 (1) , 89
Open AccessEvaluating temozolomide for pediatric adamantinomatous craniopharyngiomas using microspheroid-based drug screening
Purpose: Pediatric adamantinomatous craniopharyngioma (ACP) is the most common tumor of the diencephalic–pituitary axis in children. Although histologically benign, pediatric ACP is frequently associated with substantial endocrine dysfunction and neurological complications. The gold-standard treatment is complete surgical resection; however, because of the tumor’s location, total removal is often not feasible. Consequently, several authors recommend radiotherapy as an adjuvant option. Nevertheless, partial resections are frequently followed by recurrence, and repeated surgical interventions increase morbidity and impair quality of life. Thus, adjuvant therapeutic strategies capable of controlling this tumor should be encouraged. Methods: We analyzed seven fresh tumor specimens ACP from patients < 18 years of age using a chemoresistance platform ( Bioverso Test , Ziel Biosciences , São Paulo, Brazil). These cases demonstrated widespread resistance to most chemotherapeutic agents tested. Temozolomide (500 µM) was the only drug that showed consistent and significant sensitivity. Results: Based on these findings, we initiated treatment in a 14-year-old patient with recurrent ACP who had previously undergone multiple surgical procedures and radiotherapy. The tumor involved the left cavernous sinus and extended into the sphenoid sinus. Clinically, the patient was amaurotic and presented with panhypopituitarism. The patient received temozolomide (200 mg/m 2 /day for 5 consecutive days in 28-day cycles). After completing 12 cycles of chemotherapy, there was a notable regression of the lesion, with approximately 50% reduction in total tumor volume. Conclusion: These findings suggest that temozolomide may represent a promising therapeutic option for controlling ACP.
- Open Access
- 5 February 2026
- Published by S. Karger AG in Pediatric Neurosurgery
- p. 1-8
Case Report: Primary Fourth Ventricle Outlet Obstruction in Childhood – New Clinical Insights and Long-Term Outcome
Introduction: Primary fourth ventricle outlet obstruction (PFVOO) is a rare cause of obstructive hydrocephalus in children. Diagnosis often requires high clinical suspicion and advanced magnetic resonance imaging (MRI) sequences, and the optimal management remains a matter of debate. Case Presentation: We report a 3-year-old girl with unexplained tetraventricular hydrocephalus who presented with progressive macrocephaly, intermittent headaches, and atypical stereotyped head movements. She had previously undergone ventriculoperitoneal shunting in infancy, which failed after 18 months. High-resolution 3D-CISS MRI confirmed a patent aqueduct and a membranous obstruction at the foramen of Magendie, establishing the diagnosis of idiopathic PFVOO. An endoscopic third ventriculostomy (ETV) was performed uneventfully, and postoperative MRI confirmed ventricular size reduction. The patient remains clinically stable 2 years later, representing one of the longest pediatric follow-ups reported after ETV for PFVOO. Conclusion: PFVOO should be included in the differential diagnosis of unexplained tetraventricular hydrocephalus in children when conventional imaging is inconclusive. Advanced MRI sequences such as 3D-CISS are valuable for identifying subtle outlet obstructions. This case, extending the pediatric follow-up to 2 years, reinforces ETV as a safe and durable first-line treatment option in selected patients with PFVOO.
- 5 February 2026
- Published by S. Karger AG in Pediatric Neurosurgery
- p. 1-8
Open AccessCase Report: Primary Fourth Ventricle Outlet Obstruction in Childhood – New Clinical Insights and Long-Term Outcome
Introduction: Primary fourth ventricle outlet obstruction (PFVOO) is a rare cause of obstructive hydrocephalus in children. Diagnosis often requires high clinical suspicion and advanced magnetic resonance imaging (MRI) sequences, and the optimal management remains a matter of debate. Case Presentation: We report a 3-year-old girl with unexplained tetraventricular hydrocephalus who presented with progressive macrocephaly, intermittent headaches, and atypical stereotyped head movements. She had previously undergone ventriculoperitoneal shunting in infancy, which failed after 18 months. High-resolution 3D-CISS MRI confirmed a patent aqueduct and a membranous obstruction at the foramen of Magendie, establishing the diagnosis of idiopathic PFVOO. An endoscopic third ventriculostomy (ETV) was performed uneventfully, and postoperative MRI confirmed ventricular size reduction. The patient remains clinically stable 2 years later, representing one of the longest pediatric follow-ups reported after ETV for PFVOO. Conclusion: PFVOO should be included in the differential diagnosis of unexplained tetraventricular hydrocephalus in children when conventional imaging is inconclusive. Advanced MRI sequences such as 3D-CISS are valuable for identifying subtle outlet obstructions. This case, extending the pediatric follow-up to 2 years, reinforces ETV as a safe and durable first-line treatment option in selected patients with PFVOO.